CEBPZ and acute myeloid leukemia: Although the previously reported mediocre OS and high relapse rate were confirmed in this cohort, the 10-year OS of 84.4% among the CBF-AML patients were relatively good, especially given the number of patients who were diagnosed many years ago. In 2015, AML–Berlin-Frankfurt-Münster (BFM)-98 Study showed the favorable outcome in the subgroups of patients with inv(16) and t(8;21), with an 5-years OS of 87 and 91%, and the 5-years CIR were 16% and 12%, respectively [4].